Sheel Patel
Hematology & Oncology · St Petersburg, FLNPI 1942566567
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.8% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,748 and has fallen 99.3% since, to $18 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 263 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$668
- Novartis$448
- Amgen$408
- Johnson & Johnson$375
- Astellas Pharma US Inc$354
- Daiichi Sankyo Inc.$330
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,05597%
- Education$1673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 30 | $668 |
| Novartis | 23 | $448 |
| Amgen | 20 | $408 |
| Johnson & Johnson(2 entities) | 20 | $375 |
| Astellas Pharma US Inc | 14 | $354 |
| Daiichi Sankyo Inc. | 7 | $330 |
| E.r. Squibb & Sons, L.L.C. | 22 | $318 |
| Merck | 18 | $314 |
| Lilly USA, LLC | 17 | $297 |
| Teva Pharmaceuticals USA, Inc. | 2 | $163 |
| Eisai Inc. | 8 | $158 |
| Pfizer | 9 | $135 |
| Boehringer Ingelheim | 6 | $111 |
| Seagen Inc. | 7 | $99 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $91 |
| Incyte Corporation | 5 | $89 |
| Bayer | 4 | $68 |
| Genentech USA, Inc. | 4 | $65 |
| EMD Serono, Inc. | 4 | $65 |
| Gilead(2 entities) | 4 | $59 |
| Bristol Myers Squibb | 4 | $58 |
| Array Biopharma Inc | 3 | $57 |
| AbbVie | 3 | $51 |
| Rigel Pharmaceuticals, Inc. | 3 | $48 |
| Puma Biotechnology, Inc. | 3 | $47 |
| Karyopharm Therapeutics Inc. | 2 | $40 |
| Portola Pharmaceuticals, LLC | 2 | $39 |
| Foundation Medicine, Inc. | 1 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $34 |
| Ipsen Biopharmaceuticals, Inc | 2 | $26 |
| Exelixis Inc. | 2 | $24 |
| Sanofi | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $20 |
| Beigene USA, Inc. | 1 | $19 |
| Aurobindo Pharma USA, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Acrotech Biopharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INJECTAFER$250
- LYNPARZA$118
- IMFINZI$112
How this compares
$5,221 in reported general payments places this provider in the 50th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in St Petersburg
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
- Daniel LandauOrlando$1.8M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
- Vamsidhar VelchetiJacksonville$966K
- Shahram MoriOrlando$952K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.